Progress and promise

Stroke: Challenges, Progress, and Promise

Melatonin in cancer management: progress and promise.

Physiologic and pharmacologic concentrations of the pineal hormone melatonin have shown chemopreventive, oncostatic, and tumor inhibitory effects in a variety of in vitro and in vivo experimental models of neoplasia. Multiple mechanisms have been suggested for the biological effects of melatonin. Not only does melatonin seem to control development alone but also has the potential to increase th...

Oncolytic Bluetongue Viruses: Promise, Progress, and Perspectives

Humans are sero-negative toward bluetongue viruses (BTVs) since BTVs do not infect normal human cells. Infection and selective degradation of several human cancer cell lines but not normal ones by five US BTV serotypes have been investigated. We determined the susceptibilities of many normal and human cancer cells to BTV infections and made comparative kinetic analyses of their cytopathic effec...

Stem Cell Research: Promise and Progress

Figure 1. Rudolf Jaenisch, MD, ISSCR President, 2014-2015. Photograph: Kathleen Dooher. The field of stem cell research has continued to advance at a terrific pace over the past year, with continued improvements in technology allowing us to interrogate the pathways underpinning development, injury, and repair of our cells, tissues, and organs. We have seen leaps forward in the translation of th...

Cannabinoids for cancer treatment: progress and promise.

Cannabinoids are a class of pharmacologic compounds that offer potential applications as antitumor drugs, based on the ability of some members of this class to limit inflammation, cell proliferation, and cell survival. In particular, emerging evidence suggests that agonists of cannabinoid receptors expressed by tumor cells may offer a novel strategy to treat cancer. Here, we review recent work ...